Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors Meeting Abstract
| Authors: | Li, B. T.; Lee, K. W.; Pegram, M.; Sharma, M. R.; Lee, J.; Spira, A. I.; Kang, Y. K.; Moore, K. N.; Rasco, D.; Hanna, G. J.; Weinberg, B. A.; Yu, T.; Alonso, M.; Ptacek, J.; Yin, M.; Tapia, C.; Xu, L.; Perez, E. A.; Dumbrava, E. E. |
| Abstract Title: | Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S462 |
| End Page: | S463 |
| Language: | English |
| ACCESSION: | WOS:001087480200642 |
| DOI: | 10.1016/j.annonc.2023.09.1843 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 657MO -- Source: Wos |
